Back to dashboard
CommercialCoverageMedium impact

08.01.82c, Anifrolumab-fnia (Saphnelo®)

Independence Blue Cross·Rheumatology, Dermatology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

The policy for Anifrolumab-fnia (Saphnelo®), a specialty pharmaceutical drug, has been updated for commercial insurance plans. This appears to be a reissue of an existing policy with an effective date of May 28, 2025.

Action Required

Action needed
By May 28, 2025: Review the complete policy document at the provided URL to understand specific coverage changes for Anifrolumab-fnia (Saphnelo®). Update billing procedures and prior authorization requirements as needed for this specialty pharmaceutical. Contact the insurance company for detailed billing guidelines if not clearly specified in the full policy.

Related policy hubs